



REMARKS

Entry of this preliminary amendment is respectfully requested.

This application is a divisional of copending application no. 09/420,347. Claims 3-6, 8-15, 17, 19-22, 25, 35, 37-42 and 45-49 have been cancelled without prejudice or disclaimer. Claims 1, 2, 7, 16, 18, 23, 24, 26-34, 36, and 43-44 are amended to remove nonelected subject matter and to correct multiple dependencies. Claims 50-54 have been added. New claims 50-54 rewrite original claims 37, 41, and subject matter cancelled from pending claim 44. Claims 1, 2, 7, 16, 18, 23, 24, 26-34, 36, 43-44, and 50-54 are based on the corresponding claims as originally filed in the parent application and are directed to the subject matter of **Group II** which has not elected in the parent application. No new matter is added.

Accordingly, claims 1, 2, 7, 16, 18, 23, 24, 26-34, 36, 43-44, and 50-54 are pending and at issue in this application.

It is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Date: November 27, 20001

Respectfully submitted,

Peter J. Waibel, Reg. No. 43,228 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123

23650

PATENT TRADEMARK OFFICE



1. (Amended) A compound of formula (Ia)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

wherein ring A_{\bullet} fused to the ring containing X and N_{\bullet} represents a 5-6 membered cyclic ring[,] optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or C_{1-12} alkyl, C_{4-12} -alkenynyl, C_{2-12} -alkenyl, C_{2-12} -alkenyl, C_{1-12} alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxy C_{1-12} alkyl, amino, acylamino, C_{1-12} alkyl-amino, arylamino, aralkylamino, amino C_{1-12} alkyl, C_{1-12} alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C_{1-12} alkoxy C_{1-12} alkyl, aryloxy C_{1-12} alkyl, aralkoxy C_{1-12} alkyl, C_{1-12} alkyl, C_{1-12} alkyl, C_{1-12} alkyl, aryloxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, - COR^{11} , or - $SO_{2}R^{12}$, wherein R^{11} and R^{12} independently of each other are selected from hydroxy, halogen, perhalomethyl, C_{1-6} alkoxy or amino optionally substituted with one or more C_{1-6} alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

ring B, fused to the ring containing X and N, represents a 5-6 membered cyclic ring[,] optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or C_{1-12} alkyl, C_{4-12} -alkenynyl, C_{2-12} -alkenyl, C_{2-12} -alkynyl,

 C_{1-12} alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxy C_{1-12} alkyl, amino, acylamino, C_{1-12} alkyl-amino, arylamino, aralkylamino, amino C_{1-12} alkyl, C_{1-12} alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C_{1-12} alkoxy C_{1-12} alkyl, aralkoxy C_{1-12} alkyl, C_{1-12} alkyl, thio, thio C_{1-12} alkyl, C_{1-12} alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR¹¹, or -SO₂R¹², wherein R¹¹ and R¹² independently of each other are selected from hydroxy, halogen, perhalomethyl, C_{1-6} alkoxy or amino optionally substituted with one or more C_{1-6} alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

X is [a valence bond], -(CHR 9)-, [-(CHR 9)-CH $_2$ -, -CH=CH-, -O-, -O-(CHR 9)-, -S-(CHR 9)-, -(NR 9)-CH $_2$ -, -(CHR 9)-CH=CH-, -(CHR 9)-CH $_2$ -CH $_2$ -,] -(C=O)-, [-O-CH $_2$ -O-, -(NR 9)-, -(NR 9)-S(O $_2$)-, -CH=(CR 9)-, -(CO)-(CHR 9)-, -CH $_2$ -(SO)-, -S-, -(SO)-, -(SO $_2$)-, -CH $_2$ -(SO $_2$)-, -CH $_2$ -O-CH $_2$ -,] wherein R 9 is hydrogen, halogen, hydroxy, nitro, cyano, formyl, C $_{1-12}$ alkyl, C $_{1-12}$ alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, C $_{1-12}$ alkyl-amino, arylamino, aralkylamino, aminoC $_{1-12}$ alkyl, C $_{1-12}$ alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C $_{1-12}$ alkoxyC $_{1-12}$ alkyl, aryloxyC $_{1-12}$ alkyl, aralkoxyC $_{1-12}$ alkyl, C $_{1-12}$ alkylthio, thioC $_{1-12}$ alkyl, C $_{1-12}$ alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR $_1$ 1, or -SO $_2$ R $_2$ 2, wherein R $_1$ 1 and R $_2$ 2 independently of each other are selected from hydroxy, halogen, C $_{1-6}$ alkoxy, amino optionally substituted with one or more C $_{1-6}$ alkyl, perhalomethyl or aryl;

Q is -O-, -S-, > SO₂, > NR¹³, wherein R¹³ is hydrogen or C₁₋₆alkyl,

Ar represents arylene, heteroarylene, or a divalent heterocyclic group optionally substituted with one or more C_{1-6} alkyl or aryl;

R⁵ represents hydrogen, hydroxy, halogen, C₁₋₁₂alkoxy, C₁₋₁₂alkyl, C₄₋₁₂-alkenynyl,



 C_{2-12} -alkenyl, C_{2-12} -alkynyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R^5 forms a bond together with R^6 ,

 R^6 represents hydrogen, hydroxy, halogen, C_{1-12} alkoxy, C_{1-12} alkyl, C_{4-12} -alkenynyl, C_{2-12} -alkenyl, C_{2-12} -alkynyl, acyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R^6 forms a bond together with R^5 ,


 R^7 represents hydrogen, C_{1-12} alkyl, C_{4-12} -alkenynyl, C_{2-12} -alkenyl, C_{2-12} -alkynyl, aryl, aralkyl, C_{1-12} alkoxy C_{1-12} alkyl, C_{1-12} alkyl, aryloxycarbonyl, aryloxycarbonyl, C_{1-12} alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups[;], optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

 R^8 represents hydrogen, C_{1-12} alkyl, C_{4-12} -alkenynyl, C_{2-12} -alkenyl, C_{2-12} -alkynyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

Y represents oxygen, sulphur or NR^{10} , where R^{10} represents hydrogen, C_{1-12} alkyl, aryl, hydroxy C_{1-12} alkyl or aralkyl groups or when Y is NR^{10} , R^8 and R^{10} may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C_{1-6} alkyl;

n is an integer ranging from 1 to 4 and m is an integer ranging from 0 to 1[, provided that A or B does not represent phenyl]; or a pharmaceutically acceptable salt thereof.

2. (Amended) [A] <u>The</u> compound according to claim 1, wherein ring A, fused to the ring containing X and N, represents a 5-6 membered cyclic ring[,] optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, C₁₋₇alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC₁₋₇alkyl, amino, acylamino, C₁₋₇alkyl-amino, arylamino, aralkylamino, aminoC₁₋₇alkyl, C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl, C₁₋₇alkyl, C₁₋₇alkyl, C₁₋₇alkoxyCarbonylamino,



7. (Amended) [A] The compound according to [anyone of the preceding claims] claim 1, wherein ring B₂ fused to the ring containing X and N₂ represents a 5-6 membered cyclic ring[,] optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkenyl, C₁₋₇alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC₁₋₇alkyl, amino, acylamino, C₁₋₇alkyl-amino, arylamino, aralkylamino, aminoC₁₋₇alkyl, C₁₋₇alkoxyC₁₋₇alkyl, aryloxyC₁₋₇alkyl, aralkoxyC₁₋₇alkyl, C₁₋₇alkylthio, thioC₁₋₇alkyl, C₁₋₇alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR¹¹, or -SO₂R¹², wherein R¹¹ and R¹² independently of each other are selected from hydroxy, perhalomethyl or amino optionally substituted with one or more C₁. ⁶alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy or cyano.

amino optionally substituted with one or more C_{1.6}alkyl, perhalomethyl or aryl;

optionally substituted with one or more halogen, perhalomethyl, hydroxy or cyano.

- 16. (Amended) [A] The compound according to [anyone of the preceding claims] claim 1 wherein Q is -O- or -S-.
- [A] The compound according to [anyone of the preceding claims] claim 1 wherein Ar represents arylene, heteroarylene, or a divalent heterocyclic group optionally substituted with one or more C₁₋₆alkyl or aryl;

 R⁵ represents hydrogen, hydroxy, halogen, C₁₋₇alkoxy, C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl; or R⁵ forms a bond together with R⁶,

 R⁶ represents hydrogen, hydroxy, halogen, C₁₋₇alkoxy, C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl; or R⁶ forms a bond together with R⁵,

 R⁷ represents hydrogen, C₁₋₇alkyl, C₄₋₇-alkenynyl, C₂₋₇-alkenyl, C₂₋₇-alkynyl, aryl, aralkyl, C₁₋₇alkoxyC₁₋₇alkyl, C₁₋₇alkoxyC₁₋₇alkyl, C₁₋₇alkoxyCarbonyl, aryloxycarbonyl, C₁₋₇alkylaminocarbonyl, arylaminocarbonyl, heterocyclyl, heteroaryl or heteroaralkyl groups;



 R^8 represents hydrogen, $C_{1.7}$ alkyl, $C_{4.7}$ -alkenynyl, $C_{2.7}$ -alkenyl, $C_{2.7}$ -alkynyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl;

Y represents oxygen, sulphur or NR^{10} , where R^{10} represents hydrogen, $C_{1.7}$ alkyl, hydroxy $C_{1.7}$ alkyl;

n is an integer ranging from 2 to 3 and m is an integer ranging from 0 to 1.

- 23. (Amended) [A] <u>The</u> compound according to [anyone of the preceding claims] <u>claim 1</u> wherein A is 5 membered cyclic ring containing S.
- 24. (Amended) [A] <u>The</u> compound according to [anyone of the preceding claims] <u>claim 1</u> wherein B is 5 membered cyclic ring containing S.
- 26. (Amended) [A] The compound according to [anyone of the preceding claims] claim 1 wherein n is 2.
- 27. (Amended) [A] <u>The</u> compound according to [anyone of the preceding claims] <u>claim 1</u> wherein Q is -O-.
- 28. (Amended) [A] <u>The</u> compound according to [anyone of the preceding claims] <u>claim 1</u> wherein m is 1.
- 29. (Amended) [A] <u>The</u> compound according to [anyone of the preceding claims] <u>claim 1</u> wherein Ar is phenylene.

[In another preferred embodiment, the present invention is concerned with compounds of formula I wherein R^5 is H.]

- 30. (Amended) [A] <u>The</u> compound according to [anyone of the preceding claims] <u>claim 1</u> wherein R⁶ is H.
- 31. (Amended) [A] <u>The</u> compound according to [anyone of the preceding claims] <u>claim 1</u> wherein R⁷ is ethyl.



- 32. (Amended) [A] <u>The</u> compound according to [anyone of the preceding claims] <u>claim 1</u> wherein Y is oxygen.
- 33. (Amended) [A] <u>The</u> compound according to [anyone of the preceding claims] <u>claim 1</u> wherein R⁸ is H.
- 34. (Amended) The compound according to claim 1 which is:
- [3-{4-[2-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,
- 3-{4-[2-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-ethoxy]-phenyl}-2-methoxy-propionic acid,
- 3-{4-[2-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-ethoxy]-phenyl}-2-propoxy-propionic acid,
- 3-{4-[2-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-ethoxy]-phenyl}-2-benzyloxy-propionic acid,
- $3-\{4-[2-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-ethyl]-phenyl\}-2-ethoxy-propionic acid,$
- 3-{4-[2-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-ethyl]-phenyl}-2-methoxy-propionic acid,
- 3-{4-[2-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-ethyl]-phenyl}-2-propoxy-propionic acid,
- $3-\{4-[2-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-ethyl]-phenyl\}-2-benzyloxy-propionic acid,$
- 3-{4-[1-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-methoxy]-phenyl}-2-ethoxy-propionic acid,
- 3-{4-[1-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-methoxy]-phenyl}-2-methoxy-propionic acid,
- 3-{4-[1-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-methoxy]-phenyl}-2-benzyloxy-propionic acid,
- 3-{4-[3-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid,





3-{4-[3-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-propoxy]-phenyl}-2-methoxy-propionic acid,

3-{4-[3-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-propoxy]-phenyl}-2-benzyloxy-propionic acid,


3-{4-[3-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-propyl]-phenyl}-2-ethoxy-propionic acid,

3-{4-[3-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-propyl]-phenyl}-2-methoxy-propionic acid,


3-{4-[3-(8,9-Dihydro-3,5-dithia-4-aza-cyclopenta[f]azulen-4-yl)-propyl]-phenyl}-2-benzyloxy-propionic acid,]

2-Ethoxy-3-(4-(2-(9H-1,8,10-triaza-anthracen-10-yl)-ethoxy)-phenyl)-propionic acid, 2-methoxy-3-(4-(2-(9H-1,8,10-triaza-anthracen-10-yl)-ethoxy)-phenyl)-propionic acid, 2-propoxy-3-(4-(2-(9H-1,8,10-triaza-anthracen-10-yl)-ethoxy)-phenyl)-propionic acid, 2-benzyloxy-3-(4-(2-(9H-1,8,10-triaza-anthracen-10-yl)-ethoxy)-phenyl)-propionic acid, 2-ethoxy-3-(4-(1-(9H-1,8,10-triaza-anthracen-10-yl)-methoxy)-phenyl)-propionic acid, 2-methoxy-3-(4-(1-(9H-1,8,10-triaza-anthracen-10-yl)-methoxy)-phenyl)-propionic acid, 2-benzyloxy-3-(4-(1-(9H-1,8,10-triaza-anthracen-10-yl)-methoxy)-phenyl)-propionic acid, 2-ethoxy-3-(4-(3-(9H-1,8,10-triaza-anthracen-10-yl)-propoxy)-phenyl)-propionic acid, 2-propoxy-3-(4-(3-(9H-1,8,10-triaza-anthracen-10-yl)-propoxy)-phenyl)-propionic acid, 2-methoxy-3-(4-(3-(9H-1,8,10-triaza-anthracen-10-yl)-propoxy)-phenyl)-propionic acid, 2-benzyloxy-3-(4-(3-(9H-1,8,10-triaza-anthracen-10-yl)-propoxy)-phenyl)-propionic acid, 2-ethoxy-3-(4-(3-(9H-1,8,10-triaza-anthracen-10-yl)-propyl)-phenyl)-propionic acid, 2-propoxy-3-(4-(3-(9H-1,8,10-triaza-anthracen-10-yl)-propyl)-phenyl)-propionic acid, 2-methoxy-3-(4-(3-(9H-1,8,10-triaza-anthracen-10-yl)-propyl)-phenyl)-propionic acid, 2-benzyloxy-3-(4-(3-(9H-1,8,10-triaza-anthracen-10-yl)-propyl)-phenyl)-propionic acid, [2-ethoxy-3-(4-(2-(4,5,9-triaza-fluoren-9-yl)-ethoxy)-phenyl)-propionic acid, 2-methoxy-3-(4-(2-(4,5,9-triaza-fluoren-9-yl)-ethoxy)-phenyl)-propionic acid, 2-propoxy-3-(4-(2-(4,5,9-triaza-fluoren-9-yl)-ethoxy)-phenyl)-propionic acid, 2-ethoxy-3-(4-(1-(4,5,9-triaza-fluoren-9-yl)-methoxy)-phenyl)-propionic acid, 2-methoxy-3-(4-(1-(4,5,9-triaza-fluoren-9-yl)-methoxy)-phenyl)-propionic acid, 2-benzyloxy-3-(4-(1-(4,5,9-triaza-fluoren-9-yl)-methoxy)-phenyl)-propionic acid,

2-ethoxy-3-(4-(3-(4,5,9-triaza-fluoren-9-yl)-propoxy)-phenyl)-propionic acid,



3-(4-(3-(dithieno[2,3-b;3',2'-d]pyrrol-7-yl)-propoxy)-phenyl)-2-methoxy-propionic acid, 3-(4-(3-(dithieno[2,3-b;3',2'-d]pyrrol-7-yl)-propoxy)-phenyl)-2-propoxy-propionic acid, 3-(4-(3-(dithieno[2,3-b;3',2'-d]pyrrol-7-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid, 3-(4-(3-(dithieno[2,3-b;3',2'-d]pyrrol-7-yl)-propyl)-phenyl)-2-ethoxy-propionic acid, 3-(4-(3-(dithieno[2,3-b;3',2'-d]pyrrol-7-yl)-propyl)-phenyl)-2-methoxy-propionic acid, 3-(4-(3-(dithieno[2,3-b;3',2'-d]pyrrol-7-yl)-propyl)-phenyl)-2-propoxy-propionic acid, 3-(4-(3-(dithieno[2,3-b;3',2'-d]pyrrol-7-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid, 3-(4-(2-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid, 3-(4-(2-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid, 3-(4-(2-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid, 3-(4-(2-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid, 3-(4-(1-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid, 3-(4-(1-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-methoxy)-phenyl)-2-methoxy-propionic acid, 3-(4-(1-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-methoxy)-phenyl)-2-propoxy-propionic acid, 3-(4-(1-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-methoxy)-phenyl)-2-benzyloxy-propionic acid, 3-(4-(3-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid, 3-(4-(3-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-propoxy)-phenyl)-2-propoxy-propionic acid, 3-(4-(3-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-propoxy)-phenyl)-2-methoxy-propionic acid, 3-(4-(3-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid, 3-(4-(3-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-propyl)-phenyl)-2-ethoxy-propionic acid, 3-(4-(3-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-propyl)-phenyl)-2-propoxy-propionic acid, 3-(4-(3-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-propyl)-phenyl)-2-methoxy-propionic acid, 3-(4-(3-(difurano[2,3-b;3',2'-d]pyrrol-7-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid,] 3-(4-(2-(4H-1,7-dithia-8-aza-s-indacen-8-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid, 3-(4-(2-(4H-1,7-dithia-8-aza-s-indacen-8-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid, 3-(4-(2-(4H-1,7-dithia-8-aza-s-indacen-8-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid, 3-(4-(2-(4H-1,7-dithia-8-aza-s-indacen-8-yl)-ethoxy)-pheny)l-2-benzyloxy-propionic acid, 3-(4-(1-(4H-1,7-dithia-8-aza-s-indacen-8-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid, 3-(4-(1-(4H-1,7-dithia-8-aza-s-indacen-8-yl)-methoxy)-phenyl)-2-methoxy-propionic acid, 3-(4-(1-(4H-1,7-dithia-8-aza-s-indacen-8-yl)-methoxy)-pheny)l-2-propoxy-propionic acid, 3-(4-(1-(4H-1,7-dithia-8-aza-s-indacen-8-yl)-methoxy)-phenyl)-2-benzyloxy-propionic acid, 3-(4-(3-(4H-1,7-dithia-8-aza-s-indacen-8-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,




2-ethoxy-3-(4-(3-(4-oxa-1,7-dithia-8-aza-s-indacen-8-yl)-propoxy)-phenyl)-propionic acid, 2-methoxy-3-(4-(3-(4-oxa-1,7-dithia-8-aza-s-indacen-8-yl)-propoxy)-phenyl)-propionic acid, 2-propoxy-3-(4-(3-(4-oxa-1,7-dithia-8-aza-s-indacen-8-yl)-propoxy)-phenyl)-propionic acid, 2-benzyloxy-3-(4-(3-(4-oxa-1,7-dithia-8-aza-s-indacen-8-yl)-propoxy)-phenyl)-propionic acid,

2-ethoxy-3-(4-(3-(4-oxa-1,7-dithia-8-aza-s-indacen-8-yl)-propyl)-phenyl)-propionic acid, 2-methoxy-3-(4-(3-(4-oxa-1,7-dithia-8-aza-s-indacen-8-yl)-propyl)-phenyl)-propionic acid, 2-propoxy-3-(4-(3-(4-oxa-1,7-dithia-8-aza-s-indacen-8-yl)-propyl)-phenyl)-propionic acid, or

2-benzyloxy-3-(4-(3-(4-oxa-1,7-dithia-8-aza-s-indacen-8-yl)-propyl)-phenyl)-propionic acid; or a pharmaceutically acceptable salt thereof.

36. (Amended) A pharmaceutical composition comprising[,] as an active ingredient, [a] the compound according to [any one of the preceding compound claims] claim 1 or a



- 43. (Amended) A method for the treatment [and/or prevention] of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR), the method comprising administering to a subject in need thereof an effective amount of [a] the compound according to [any one of the preceding compound claims] claim 1 or a pharmaceutically acceptable salt thereof[, or of a composition according to anyone of the preceding claims 36-41].
- 44. (Amended) A method for the treatment [and/or prevention] of diabetes [and/or obesity], the method comprising administering to a subject in need thereof an effective amount of [a] the compound according to [anyone of the preceding compound claims] claim 1 or a pharmaceutically acceptable salt thereof[, or of a composition according to anyone of the preceding claims 36-41].